As the Institute for Clinical and Economic Review (ICER) prepares to update its final value proposal framework, it has been aided by the constructive comments from different stakeholders, said ICER president Steve Pearson, MD, MSc. He predicts that coming years will see continued interest in how to utilize such frameworks.
As the Institute for Clinical and Economic Review (ICER) prepares to update its final value proposal framework, it has been aided by the constructive comments from different stakeholders, said ICER president Steve Pearson, MD, MSc. He predicts that coming years will see continued interest in how to utilize such frameworks.
Transcript (slightly modified)
How does ICER plan to update its value framework?
ICER has gone through a fairly long process now of getting public comment in 2 separate phases on our value framework, and we’ve actually received tremendously helpful suggestions in both phases. It’s taken us longer than we thought to get through the second phase, so we’ve been a bit delayed in announcing our final update proposals, but that should come out now within the next few weeks.
We’re really looking forward to continuing to work with stakeholders, because we learn as they learn as we continue to work together on these reports and as we go together to these public meetings. There will be further work to be done together, but we’re very exciting about putting out our update proposals and moving forward with the stakeholder groups.
What has been the uptake and use of value frameworks?
The growth of the use, if you will, the downloads have been going up and up. We hear a lot of anecdotal evidence, and there have been some surveys on the number of payers that are using our research to support both coverage decisions but also considerations around pricing and payment models.
I do think that there’s going to be continued interest in trying to figure out how to use value frameworks going forward. The value frameworks that are out there have very different histories, but also very different purposes, and so they’re kind of structured differently to meet those different goals. I think people are gaining more awareness of the reason that value frameworks don’t all look the same, because they have different functions, if you will.
I do think that a general purpose of trying to make as clear as possible and as fair as possible an approach to judging value is something that our health system really needs.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More